Lorenzo Brunetti

Ancona, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Nuclear Transcriptional Condensates as Drivers and Therapeutic Targets in NPM1-mutated AML.

Nuclear Transcriptional Condensates as Drivers and Therapeutic Targets in NPM1-mutated AML.

Journal: Blood

Published: January 06, 2026

Nuclear transcriptional condensates as drivers and therapeutic targets in NPM1-mutated AML.

Nuclear transcriptional condensates as drivers and therapeutic targets in NPM1-mutated AML.

Journal: Blood

Published: January 06, 2026

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Journal: Blood cancer journal

Published: December 04, 2025

NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort.

NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort.

Journal: Hematological oncology

Published: November 10, 2025

Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Journal: Blood cancer journal

Published: July 29, 2025

Nuclear Phase Separation Drives NPM1-mutant Acute Myeloid Leukemia.

Nuclear Phase Separation Drives NPM1-mutant Acute Myeloid Leukemia.

Journal: bioRxiv : the preprint server for biology

Published: June 12, 2025

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Journal: Blood advances

Published: May 19, 2025

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Journal: Blood advances

Published: May 19, 2025

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Journal: Blood advances

Published: May 19, 2025

Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation.

Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation.

Journal: American journal of hematology

Published: March 28, 2025

Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents.

Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents.

Journal: American journal of hematology

Published: September 05, 2024

Mutant NPM1 marginally impacts ribosome footprint in acute myeloid leukemia cells.

Mutant NPM1 marginally impacts ribosome footprint in acute myeloid leukemia cells.

Journal: EJHaem

Published: July 25, 2024

Showing 1-12 of 59

Last Updated: 09/26/2026